LEVOTHYROXINE SODIUM (levothyroxine sodium) by Fresenius Kabi is synthesis. First approved in 2019.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
Levothyroxine sodium is a synthetic thyroid hormone replacement therapy administered intravenously as a solution formulation. It works by diffusing into cell nuclei and binding to thyroid receptor proteins, activating gene transcription and protein synthesis to replace deficient thyroid hormone. The drug's physiological effects are mediated primarily through conversion to triiodothyronine (T3) in peripheral tissues.
Product is in peak commercial lifecycle with established market presence; team size and growth trajectory unclear due to limited competitive data.
synthesis. Triiodothyronine (T3) and levothyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
Worked on LEVOTHYROXINE SODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on levothyroxine sodium offers stable, predictable career development within a niche hospital/acute care specialty market under Fresenius Kabi sponsorship. The peak lifecycle stage and competitive monopoly suggest roles focused on market penetration and customer relationship management rather than launch innovation or turnaround strategy.